Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Walnut protein powder is an investigational oral immunotherapy (OIT) being developed by the University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute for the treatment of tree nut allergies. The treatment involves the oral administration of gradually increasing doses of walnut protein to desensitize patients, thereby increasing their threshold for allergic reactions. This approach aims to induce immunological changes that reduce the risk of severe reactions upon accidental exposure to walnuts and potentially cross-reactive tree nuts like pecans. In clinical trials, such as the Phase 1/2 study NCT01546753, participants undergo an initial escalation phase followed by a build-up phase and long-term maintenance dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on walnut protein powder.